Skip to main content

Acceptability of Liquid Human Growth Hormone (hGH) [Norditropin Simple Xx®] in Adults and Children with GH Deficiency and Children with Chronic Renal Disease

Abstract

Objective

Human growth hormone (GH) is well established as a treatment for growth hormone deficiency. Recently, a new liquid GH formulation (Norditropin SimpleXx®) has become available that does not require reconstitution before subcutaneous self-administration with a new delivery system (NordiPen™) and an optional auto-injector (NordiPenmate™). In this study the acceptability and tolerability of and compliance with the liquid formulation were investigated

Design and patients

An open 6-week multicentre trial in 53 patients, including adults and children, was performed in The Netherlands. Acceptability and tolerability of the liquid GH formulation were assessed by questionnaires and compliance by both questionnaires and re-collection of GH cartridges

Main outcome measures and results

The mean daily dosage of GH was 0.24 mg/m2 (0.03 to 0.82 mg/m2) in adults and 1.13 mg/m2 (0.65 to 1.77 mg/m2) in children. Most patients (91% of adults and 89% of children) preferred to continue on the new GH formulation rather than the previously used formulation. This was mainly due to the easier and less time-consuming procedure and the good tolerance of the drug. Self-reported compliance also improved, but this could not be proven due to poor return of study cartridges

Conclusions

The use of the liquid GH formulation Norditropin SimpleXx® with the NordiPen™ device and optional use of the NordiPenmate™ device was well accepted by both adults and children. This was mainly due to the avoidance of reconstitution and the ease of handling of the injection device

This is a preview of subscription content, access via your institution.

Table I
Table II
Table III

Notes

  1. 1.

    1 The use of tradenames is for product identification only and does not imply endorsement.

References

  1. 1.

    Oyarzabal M, Aliaga M, Chueca M, et al. Multicentre survey on compliance with growth hormone therapy: what can be improved? Acta Paediatr 1998; 87: 387–91

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Jorgensen JT. Improvement of patient convenience in treatment with growth hormone. J Pediatr Endocrinol 1994; 7: 175–80

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Jorgensen JT, Romsing J, Rasmussen M, et al. Pain assessment of subcutaneous injections. Ann Pharmacother 1996; 30: 729–32

    PubMed  CAS  Google Scholar 

  4. 4.

    Main KM, Jorgensen JT, Hertel NT, et al. Automatic needle insertion diminishes pain during growth hormone injection. Acta Paediatr 1995; 84: 331–4

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    Chantelau E, Lee DM, Hemmann DM, et al. What makes insulin injections painful? BMJ 1991; 303: 26–7

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Smith SL, Hindmarsh PC, Brook CG. Compliance with growth hormone treatment: are they getting it? Arch Dis Child 1993; 68: 91–3

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Iyoda K, Moriwake T, Seino Y, et al. The clinical usefulness of liquid human growth hormone (hGH) (Nordtropin® SimpleXx™) in the treatment of GH deficiency. Horm Res 1999; 51 Suppl. 3: 113–5

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Muller J, Skakkebaek NE, Jacobsen BB, et al. Norditropin® SimpleXx™: a liquid human growth hormone formulation, a pen system and an auto-insertion device. Horm Res 1999; 51 Suppl. 3: 109–12

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Stanhope R, Buchanan C, Butler G, et al. An open-label acceptability study of Norditropin SimpleXx: a new liquid growth hormone formulation. J Pediatric Endocrinol Metab 2001; 14: 735–40

    CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to M. L. Drent.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Drent, M.L., Jakobsdottir, S., van Wijk, J.A.E. et al. Acceptability of Liquid Human Growth Hormone (hGH) [Norditropin Simple Xx®] in Adults and Children with GH Deficiency and Children with Chronic Renal Disease. Clin. Drug Investig. 22, 633–638 (2002). https://doi.org/10.2165/00044011-200222090-00008

Download citation

Keywords

  • Growth Hormone
  • Growth Hormone Deficiency
  • Delivery Device
  • Injection Device
  • Growth Hormone Administration